Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic ischemic events such as stroke and myocardial infarction. Given that asymptomatic patients make up a large percentage of the total PAD population, it is largely underdiagnosed, under-recognized, and undertreated. However, there is growing recognition that optimal management of PAD requires aggressive secondary prevention measures. PAD treatment is dominated by well-established generic drugs, restricting the overall market value, but emerging therapies, such as stem cell therapies, could significantly boost the market. Overall, the increasing number of prevalent cases, combined with substantial unmet needs and the development of novel therapies, makes the treatment of PAD a high-growth opportunity.
- There is a substantial treatment gap in PAD; a considerable percentage of patients remaining undiagnosed and untreated. How do thought leaders believe this treatment gap can be reduced?
- What are the key pharmacotherapeutic agents used for PAD? What are the major unmet needs, according to thought leaders?
- How active is research and development for PAD? What are thought leaders' opinions of the novel therapies in development?
- How will the PAD market grow with the emergence of new branded therapies, and how will these agents impact treatment practice?
Geographies: United States, EU5, Japan.
Primary research: 17 country-specific interviews with thought-leading PAD experts. Supported by survey data collected for this and other DRG research.
Epidemiology: Prevalence of PAD by country, acute PAD-associated events; diagnosis and drug-treated rates.
Emerging therapies: Phase III: 2 drugs; Phase II: 5 drugs.
Market forecast features: Ten-year, annualized, drug-level sales, and patient share of key PAD therapies through 2029, segmented by brands / generics.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.